CB-12181, a new azasugar-based matrix metalloproteinase/tumor necrosis factor-alpha converting enzyme inhibitor, inhibits vascular endothelial growth factor-induced angiogenesis in vitro and retinal neovascularization in vivo. (Q45965417)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | CB-12181, a new azasugar-based matrix metalloproteinase/tumor necrosis factor-alpha converting enzyme inhibitor, inhibits vascular endothelial growth factor-induced angiogenesis in vitro and retinal neovascularization in vivo. |
scientific article |
Statements
1 reference
CB-12181, a new azasugar-based matrix metalloproteinase/tumor necrosis factor-alpha converting enzyme inhibitor, inhibits vascular endothelial growth factor-induced angiogenesis in vitro and retinal neovascularization in vivo. (English)
1 reference
Yuichi Chikaraishi
1 reference
Masamitsu Shimazawa
1 reference
Koichi Yokota
1 reference
Koichiro Yoshino
1 reference
Hideaki Hara
1 reference
1 August 2009
1 reference
1 reference
6
1 reference
140-147
1 reference
3
1 reference
Identifiers
1 reference
1 reference